Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
The occurrence of naturally HCV NS resistance associated sub
2022-03-18

The occurrence of naturally HCV NS3 resistance-associated substitutions (RAS) affects virological outcome of DAA-based combination therapies [14], [15], [16], [17], [18], [19]. For the majority of NS3 protease inhibitors the frequency of natural occurrence of single RASs in HCV genotype 1-infected
-
There is increased awareness of HBV reactivation in chronic
2022-03-18

There is increased awareness of HBV reactivation in chronic HCV/HBV co-infected patients treated with DAAs [1], [2]. The recent emergence of this adverse event of DAA therapy is due to the exclusion of HBV co-infected subjects from registration clinical trials evaluating the safety of these treatmen
-
In order to determine which complex of the electron transpor
2022-03-18

In order to determine which complex of the electron transport chain is targeted by Authipyrin, a semi-intact assay was performed. The substrates of each complex were added separately in combination with Authipyrin or the respective control inhibitor. Seahorse XF plasma membrane permeabilizer (PMP) w
-
clodronate br Declaration of interest br Acknowledgments br
2022-03-18

Declaration of interest Acknowledgments This work was supported by grants from the Polish National Science Centre (PRELUDIUM grant no. 2013/11/N/NZ5/00270) and the European Commission FP7 Project Beta-JUDO (grant number 279 153), European Union EIT Health project DeTecT2D, Swedish Diabetes A
-
Several studies have found that GPR possesses a
2022-03-18

Several studies have found that GPR55 possesses a distinct pharmacology from that of CB1 and CB2, and that only certain cannabinoids act at this receptor. In transfected URMC-099 expressing hGPR55, out of more than 20 synthetic and endogenous cannabinoids evaluated, only 2 compounds, SR141716A (Rim
-
For a long time the mechanism for the TG lowering
2022-03-18

For a long time, the mechanism for the TG-lowering effect of nicotinic PHA-793887 has been thought that the lowered NEFA substrate from adipose tissue limits TG production from the liver (so-called NEFA hypothesis) [[1], [2], [3], [4]]. However, recent emerging evidences have suggested the involveme
-
Several studies have shown that the levels
2022-03-18

Several studies have shown that the levels of reactive dicarbonyls are higher in patients with diabetes as a result of hyperglycemia.49, 50, 51 Consequently, reactive dicarbonyl-derived AGEs are elevated in plasma and accumulate in tissues prone to secondary complications, including the lens, retina
-
Taken together our results show that at
2022-03-17

Taken together, our results show that, at least in the in vitro cell line model, methylation within the proximal promoter region of GHSR is an important determinant of its expression; however, to determine whether this represents a physiologically and or pathophysiologically relevant event, further
-
The overall very satisfactory potency
2022-03-17

The overall very satisfactory potency profile of compounds 7a–l suggests that 1,3,4-thiadiazole-2-carboxamide moiety was a suitable periphery group to add to the 3-phenylpropanoic Z VDVAD FMK core in order to improve affinity to FFA1. The agonist activity in this series appears to be particularly se
-
We have isolated various bioactive
2022-03-17

We have isolated various bioactive Etoposide acting by binding to the receptors of endogenous bioactive peptides such as opioid, bradykinin, neurotensin, and complements C3a and C5a etc. [24]. Rubimetide is the first example of an agonist peptide of the FPR2 of exogenous origin. Anxiolytic-like act
-
Lentiviruses are associated with immunological impairment in
2022-03-17

Lentiviruses are associated with immunological impairment in their respective hosts, and both human immunodeficiency and feline immunodeficiency viral infections increase the likelihood of secondary bacterial infections [23], [24]. Recently, Kubes et al. [25] demonstrated that feline neutrophils exh
-
In the previous paper we described the
2022-03-17

In the previous paper, we described the design and synthesis of tricyclic thiazoles as FBPase inhibitors, and a series of SAR studies led to the identification of phosphate 3 and difluoromethylenephosphonate 4 exhibiting potent FBPase inhibitory activities (IC50=13, 47nM, respectively) (Fig. 2). In
-
Chemotherapeutic approaches to glioblastoma which
2022-03-17

Chemotherapeutic approaches to glioblastoma, which are highly invasive, are still largely unsuccessful and have only a minimal impact on patients’ survival rate . New agents that target the specific molecular aberrations in the tumors are presently being investigated for their efficacy against this
-
Elacridar br Acknowledgments This research was supported by
2022-03-17

Acknowledgments This research was supported by the National Institutes of Health Grants GM58442 and GM084152, as well as the National Institutes of Health Predoctoral Training Grant 5T32GM008700-13. We thank Eric Oldfield (University of Illinois, Urbana-Champaign) for providing the FDPS inhibitor
-
A few previous studies have examined Factor
2022-03-17

A few previous studies have examined Factor Xa inhibitors for VTE prophylaxis in hip fracture patients. In a 2001 paper, Eriksson et al. studied 1250 patients with hip fractures that had been randomized to either postoperative Factor Xa inhibitor or enoxaparin [13]. Each patient received bilateral v
15843 records 469/1057 page Previous Next First page 上5页 466467468469470 下5页 Last page